Program: RRPV
Solicitation Number: RPP 24-02-OralVx
Customer: BARDA
Release Date: 09/09/2024
Submission Deadline: 11/15/2024 1PM ET
Description: BARDA is requesting project proposals from developers to advance next generation oral vaccine formulations and technologies for COVID-19 into proof-of-concept Phase 1 trials. Oral delivery of vaccines offers several potential benefits for pandemic preparedness over traditional needle/syringe-based delivery, including: ease of administration from the perspective of both those administering vaccines and people receiving vaccines; generation of mucosal immunity at the site of infection; potential for reduced cold chain reliance; and improved distribution and administration logistics.
active_solicitations
solicitation_program: RRPV
solicitation_number: RPP-24-02
solicitation_customer: BARDA
solicitation_release_date: 09/09/2024
solicitation_submission_deadline: 11/15/2024 1PM ET
solicitation_description: BARDA is requesting project proposals from developers to advance next generation oral vaccine formulations and technologies for COVID-19 into proof-of-concept Phase 1 trials. Oral delivery of vaccines offers several potential benefits for pandemic preparedness over traditional needle/syringe-based delivery, including: ease of administration from the perspective of both those administering vaccines and people receiving vaccines; generation of mucosal immunity at the site of infection; potential for reduced cold chain reliance; and improved distribution and administration logistics.
solicitation_url: https://www.rrpv.org/solicitation/nextgen-oral-formulation-vaccines-for-covid-19/